ClinicalTrials.gg
Drug

Cilofexor clinical trials

Also written GS-9674.

studies test it
12
open now
0
in phase 3
1
first study started
2013

How each study uses cilofexor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cilofexor
7
CILO
3

Development codes

GS-9674
10
Px-104
1

Studies by the year they started

12 studies that test it; most in 2016 (6)

Studies that test cilofexor, by start year
YearStudies
20131
20166
20181
20193
20211

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
8
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 0

Gilead Sciences (11) · Phenex Pharmaceuticals AG (1)

Often tested with

Tested in the same studies.

Firsocostat (4) · Selonsertib (2) · Semaglutide (1)

Studies

Open first, then newest update. How each study uses cilofexor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 12

Codes

What other systems call cilofexor · ClinicalTrials.gg INT001622

  • MeSH (NLM) C000717094cilofexorOne source NLM
  • UNII (FDA) YUN2306954CILOFEXORConfirmed FDA, NLM, Wikidata
  • Wikidata Q105334909cilofexorConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C169848CilofexorOne source FDA
  • DrugBank DB15168One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.